Biological feasibility of measles eradication

Journal of Infectious Diseases

Volumn 204, Issue SUPPL. 1, 2011, Pages

  Moss, William J ^a   Strebel, Peter ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES ANTIBODY; MEASLES VACCINE; VIRUS RNA; VIRUS ANTIBODY;

ARTICLE; BIOLOGICAL WARFARE; CLINICAL EFFECTIVENESS; COMORBIDITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; ENZYME IMMUNOASSAY; FEASIBILITY STUDY; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNOGENICITY; INFECTION CONTROL; MEASLES; MEASLES VACCINATION; MEASLES VIRUS; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROLOGY; VIRUS ATTENUATION; VIRUS CARRIER; VIRUS CULTURE; VIRUS DETECTION; VIRUS ISOLATION; VIRUS TRANSMISSION; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DISEASE CARRIER; DISEASE PREDISPOSITION; GENETICS; HEALTH; HEALTH SURVEY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; PASSIVE IMMUNIZATION; PRIMATE; PRIMATE DISEASE; REVIEW; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; DISEASE RESERVOIRS; DISEASE SUSCEPTIBILITY; GENETIC VARIATION; HIV INFECTIONS; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; INFANT; MEASLES; MEASLES VACCINE; MEASLES VIRUS; POPULATION SURVEILLANCE; PRIMATE DISEASES; PRIMATES; RNA, VIRAL; WORLD HEALTH;

EID: 79960855421     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir065     Document Type: Article

References (50)

1. Sencer DJ, Dull HB, Langmuir AD. Epidemiologic basis for eradication of measles in 1967. Public Health Rep 1967; 82:253-6.
2. The eradication of infectious diseases (Report of the dahlem workshop on the eradication of infectious diseases, Berlin, March 16-22, 1997). New York: Wiley, 1998.
3. Orenstein WA, Strebel PM, Papania M, Sutter RW, Bellini WJ, Cochi SL. Measles eradication: is it in our future? Am J Public Health 2000; 90:1521-5.
4. Jones-Engel L, Engel GA, Schillaci MA, et al. Considering humanprimate transmission of measles virus through the prism of risk analysis. Am J Primatol 2006; 68:868-79.
5. Bhatt PN, Brandt CD, Weiss R, Fox JP, Shaffer MF. Viral infections of monkeys in their natural habitat in southern India. II. Serological evidence of viral infection. Am J Trop Med Hyg 1966; 15:561-6.
6. Jones-Engel L, Engel GA, Schillaci MA, Babo R, Froehlich J. Detection of antibodies to selected human pathogens among wild and pet macaques (Macaca tonkeana) in Sulawesi, Indonesia. Am J Primatol 2001; 54:171-8.
7. Black FL. Measles endemicity in insular populations: critical community size and its evolutionary implication. J Theor Biol 1966; 11:207-11.
8. Clutton-Brock TH, Harvey PH. Primate ecology and social organization. J Zoology 1977; 183:1-30.
9. Dietz V, Rota J, Izurieta H, Carrasco P, Bellini W. The laboratory confirmation of suspected measles cases in settings of low measles transmission: conclusions from the experience in the Americas. Bull World Health Organ 2004; 82:852-7.
10. Riddell MA, Moss WJ, Hauer D, Monze M, Griffin DE. Slow clearance of measles virus RNA after acute infection. J Clin Virol 2007; 39:312-7.
11. Pan CH, Valsamakis A, Colella T, et al. Inaugural Article: Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci U S A 2005; 102:11581-8.
12. Helfand RF, Kebede S, Mercader S, Gary HE Jr., Beyene H, Bellini WJ. The effect of timing of sample collection on the detection of measles-specific IgM in serum and oral fluid samples after primary measles vaccination. Epidemiol Infect 1999; 123:451-6.
13. Uzicanin A. Field effectiveness of measles containing vaccines- literature review. Meeting of the SAGE working group for measles, Geneva, Switzerland, 2009. http://www.who.int/immunization/sage/2-Measles-vaccine- effectiveness-Uzicanin.pdf. J Infect Dis. 2011; 203. doi: 10.1093/jid/jir102.
14. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-42.
15. Permar SR, Klumpp SA, Mansfield KG, et al. Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol 2003; 77:4396-400.
16. Cutts FT, Grabowsky M, Markowitz LE. The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants. Biologicals 1995; 23:95-106.
17. Moss WJ, Scott S. WHO immunological basis for immunization series: measles. Geneva, Switzerland: World Health Organzation, 2009.
18. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 1998; 280:527-32.
19. Caceres VM, Strebel PM, Sutter RW. Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. Clin Infect Dis 2000; 31:110-9.
20. Krober MS, Stracener CE, Bass JW. Decreased measles antibody response after measles-mumps-rubella vaccine in infants with colds. JAMA 1991; 265:2095-6.
21. Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J Infect Dis 2006; 193:655-63.
22. Gay NJ. The theory of measles elimination: implications for the design of elimination strategies. J Infect Dis 2004; 189(Suppl. 1):S2-S35.
23. Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 2003; 81:61-70.
24. Scott P, Moss WJ, Gilani Z, Low N. Safety and immunogenicity of measles vaccine in HIV-infected children: systematic review and metaanalysis. J Infect Dis 2011; 203. doi: 10.1093/jid/jir071.
25. Orenstein WA, Papania MJ, Wharton ME. Measles elimination in the United States. J Infect Dis 2004; 189(Suppl. 1):S1-S3.
26. Sugerman DE, Barskey AE, Delea MG, et al. Measles outbreak in a highly vaccinated population, San Diego, 2008: Role of the intentionally undervaccinated. Pediatrics 2010; 125:747-55.
27. World Health Organization. Progress in global measles control and mortality reduction, 2000-2006. Wkly Epidemiol Rec 2007; 82:418-24.
28. Bellini WJ, Rota JS, Lowe LE, et al. Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. J Infect Dis 2005; 192:1686-93.
29. Permar SR, Moss WJ, Ryon JJ, et al. Prolonged measles virus shedding in human immunodeficiency virus-infected children, detected by reverse transcriptase-polymerase chain reaction. J Infect Dis 2001; 183: 532-8.
30. Whittle HC, Aaby P, Samb B, Jensen H, Bennett J, Simondon F. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa. Lancet 1999; 353:98-101.
31. Mossong J, Nokes DJ, Edmunds WJ, Cox MJ, Ratnam S, Muller CP. Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity. Am J Epidemiol 1999; 150:1238-49.
32. Lievano FA, Papania MJ, Helfand RF, et al. Lack of evidence of measles virus shedding in people with inapparent measles virus infections. J Infect Dis 2004; 189(Suppl. 1):S165-S170.
33. Dine MS, Hutchins SS, Thomas A, Williams I, Bellini WJ, Redd SC. Persistence of vaccine-induced antibody to measles 26-33 years after vaccination. J Infect Dis 2004; 189(Suppl. 1):S123-30.
34. Kuhne M, Brown DW, Jin L. Genetic variability of measles virus in acute and persistent infections. Infect Genet Evol 2006; 6:269-76.
35. Tamin A, Rota PA, Wang ZD, Heath JL, Anderson LJ, Bellini WJ. Antigenic analysis of current wild type and vaccine strains of measles virus. J Infect Dis 1994; 170:795-801.
36. Xu W, Tamin A, Rota JS, Zhang L, Bellini WJ, Rota PA. New genetic group of measles virus isolated in the People's Republic of China. Virus Res 1998; 54:147-56.
37. Frank SA, Bush RM. Barriers to antigenic escape by pathogens: trade-off between reproductive rate and antigenic mutability. BMC Evol Biol 2007; 7:229.
38. Parker AA, Staggs W, Dayan GH, et al. Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. N Engl J Med 2006; 355:447-55.
39. Dallaire F, De Serres G, Tremblay FW, Markowski F, Tipples G. Long-lasting measles outbreak affecting several unrelated networks of unvaccinated persons. J Infect Dis 2009; 200:1602-5.
40. Moss WJ, Cutts F, Griffin DE. Implications of the human immunodeficiency virus epidemic for control and eradication of measles. Clin Infect Dis 1999; 29:106-12.
41. Moss WJ, Monze M, Ryon JJ, Quinn TC, Griffin DE, Cutts F. Prospective study of measles in hospitalized human immunodeficiency virus (HIV)-infected and HIV-uninfected children in Zambia. Clin Infect Dis 2002; 35:189-96.
42. Scott S, Moss WJ, Cousens S, et al. The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants. Clin Infect Dis 2007; 45:1417-24.
43. Moss WJ, Scott S, Mugala N, et al. Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study. J Infect Dis 2007; 196:347-55.
44. McMorrow ML, Gebremedhin G, van den Heever J, et al. Measles outbreak in South Africa, 2003-2005. S Afr Med J 2009; 99:314-9.
45. Helfand RF, Moss WJ, Harpaz R, Scott S, Cutts F. Evaluating the impact of the HIV pandemic on measles control and elimination. Bull World Health Organ 2005; 83:329-37.
46. Otten M, Kezaala R, Fall A, et al. Public-health impact of accelerated measles control in the WHO African Region 2000-03. Lancet 2005; 366:832-9.
47. Scott S, Mossong J, Moss WJ, Cutts FT, Cousens S. Predicted impact of the HIV-1 epidemic on measles in developing countries: results from a dynamic age-structured model. Int J Epidemiol 2008; 37:356-67.
48. Meissner HC, Strebel PM, Orenstein WA. Measles vaccines and the potential for worldwide eradication of measles. Pediatrics 2004; 114:1065-9.
49. Griffin DE, Pan CH, Moss WJ. Measles vaccines. Front Biosci 2008; 13:1352-70.
50. Glass K, Kappey K, Grenfell BT. The effect of heterogeneity in measles vaccination on population immunity. Epidemiol Infect 2004; 132:675-83.